These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]
26. [Effective LDL cholesterol reduction for high risk patients]. Einecke D MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175 [No Abstract] [Full Text] [Related]
27. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954 [TBL] [Abstract][Full Text] [Related]
28. [Lipid control in high-risk patients: focus on PCSK9 inhibitors]. Filardi PP; Paolillo S; Trimarco B G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751 [TBL] [Abstract][Full Text] [Related]
29. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
30. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824 [TBL] [Abstract][Full Text] [Related]
31. How far down to push the LDL cholesterol? PCSK9 where statins fail. Simko V; Ginter E Bratisl Lek Listy; 2016; 117(4):193-4. PubMed ID: 27075380 [No Abstract] [Full Text] [Related]
32. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
33. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Hopkins PN; Defesche J; Fouchier SW; Bruckert E; Luc G; Cariou B; Sjouke B; Leren TP; Harada-Shiba M; Mabuchi H; Rabès JP; Carrié A; van Heyningen C; Carreau V; Farnier M; Teoh YP; Bourbon M; Kawashiri MA; Nohara A; Soran H; Marais AD; Tada H; Abifadel M; Boileau C; Chanu B; Katsuda S; Kishimoto I; Lambert G; Makino H; Miyamoto Y; Pichelin M; Yagi K; Yamagishi M; Zair Y; Mellis S; Yancopoulos GD; Stahl N; Mendoza J; Du Y; Hamon S; Krempf M; Swergold GD Circ Cardiovasc Genet; 2015 Dec; 8(6):823-31. PubMed ID: 26374825 [TBL] [Abstract][Full Text] [Related]
34. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163 [TBL] [Abstract][Full Text] [Related]
35. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Tavori H; Melone M; Rashid S Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623 [TBL] [Abstract][Full Text] [Related]
36. Alirocumab: First Global Approval. Markham A Drugs; 2015 Sep; 75(14):1699-705. PubMed ID: 26370210 [TBL] [Abstract][Full Text] [Related]
37. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Cicero AF; Tartagni E; Ertek S Expert Opin Drug Saf; 2014 Aug; 13(8):1023-30. PubMed ID: 24961142 [TBL] [Abstract][Full Text] [Related]
38. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
39. [Antibodies in addition to statin therapy lowers LDL cholesterol]. Bossenmayer S Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281534 [No Abstract] [Full Text] [Related]
40. Promising new therapies for the treatment of hypercholesterolemia. Valerio MG; Velayati A; Jain D; Aronow WS Expert Opin Biol Ther; 2016; 16(5):609-18. PubMed ID: 26822080 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]